|
|
|
|
|
|
|
|
|
|
|
|
|
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF NYMOX PHARMACEUTICAL CORPORATION AS OF AND
FOR THE SIX MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CURRENCY> U.S. DOLLAR
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> JUN-30-2000
<EXCHANGE-RATE> 0.00001
<CASH> 1,551,074
<SECURITIES> 0
<RECEIVABLES> 145,541
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 1,825,115
<PP&E> 1,878,529
<DEPRECIATION> 582,507
<TOTAL-ASSETS> 4,084,471
<CURRENT-LIABILITIES> 513,078
<BONDS> 0
0
0
<COMMON> 21,570,789
<OTHER-SE> 17,999,396
<TOTAL-LIABILITY-AND-EQUITY> 4,084,471
<SALES> 73,488
<TOTAL-REVENUES> 107,720
<CGS> 0
<TOTAL-COSTS> 87,227
<OTHER-EXPENSES> 2,111,089
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (2,090,596)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,090,596)
<EPS-BASIC> (0.10)
<EPS-DILUTED> (0.10)
</TABLE>
|
|